Media ReleasesSomnomed Limited

View All Somnomed Limited News

SomnoMed Announces 2018 Full Year Results and the Consolidation of the RSS Operations

22nd August 2018, SomnoMed Limited (ASX:SOM) announced today full year group revenues of $63.6 million (unaudited), representing growth of 29% over prior year. SomnoMed core revenues were $52.4 million, up 10% from 2017 and Renew Sleep Solutions (“RSS”) revenues were $11.2 million, and up from $1.6 million in 2017. The Group EBITDA loss (unaudited) for the year is $6.5 million. SomnoMed’s core division contributed a positive $3.9m to this result (+65%), with RSS’s annual loss at $10.4 million.

SomnoMed’s “Direct to Patient” business, RSS, is now nineteen months old and management has learnt a significant amount regarding the key drivers of success for the “Direct to Patient” model. After careful analysis of the performance of the centres opened to date and a better understanding of the key drivers of the business, it has been decided to reduce its operations from 12 metropolitan areas to 8, to provide the business with a stronger platform for near and long term success.

For further information please download PDF attached: 
Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.